Investigational Drug Information for CEND-1

What is the drug development status for CEND-1?

CEND-1 is an investigational drug.

There have been 5 clinical trials for CEND-1. The most recent clinical trial was a Phase 1 trial, which was initiated on March 19^th 2024.

The most common disease conditions in clinical trials are Adenocarcinoma, Pancreatic Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Cend Therapeutics Inc., Qilu Pharmaceutical Co., Ltd., and Anup Kasi.

There are one hundred and twenty US patents protecting this investigational drug and ninety-seven international patents.

Summary for CEND-1

US Patents	120
International Patents	97
US Patent Applications	303
WIPO Patent Applications	123
Japanese Patent Applications	29
Clinical Trial Progress	Phase 1 (2024-03-19)
Vendors	21

Recent Clinical Trials for CEND-1

Title	Sponsor	Phase
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma	Qilu Pharmaceutical Co., Ltd.	PHASE2
CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab	Cend Therapeutics Inc.	Phase 1/Phase 2
CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab	Anup Kasi	Phase 1/Phase 2

See all CEND-1 clinical trials

Clinical Trial Summary for CEND-1

Top disease conditions for CEND-1

Top clinical trial sponsors for CEND-1

See all CEND-1 clinical trials

US Patents for CEND-1

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
CEND-1		Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery	The Regents of the University of California (Oakland, CA)
CEND-1		XTEN conjugate compositions and methods of making same	Amunix Operating Inc. (Mountain View, CA)
CEND-1		Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides	Sanford Burnham Prebys Medical Discovery Institute
CEND-1		Solution delivery device and method	Connext Co ltd
CEND-1		Dual targeting drug carrier and application thereof	National Yang Ming Chiao Tung University NYCU
CEND-1		Hyperbranched polyglycerol-coated particles and methods of making and using thereof	Yale University

International Patents for CEND-1

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
CEND-1	Australia	AU2017206077	2036-01-08
CEND-1	Australia	AU2022200881	2036-01-08
CEND-1	Canada	CA3010711	2036-01-08
CEND-1	China	CN108601746	2036-01-08
CEND-1	European Patent Office	EP3399966	2036-01-08
CEND-1	Japan	JP2019501198	2036-01-08

Last updated: May 6, 2026

CEND-1 Development Update and Market Projection

What is CEND-1 and what does the development status indicate?

No complete, citable public record is available in the provided materials to determine: the therapeutic indication, molecular entity, modality, sponsor, mechanism of action, clinical stage, trial identifiers, enrollment status, design endpoints, or near-term readouts for CEND-1. Without those facts, a development update cannot be produced without speculation, and a market projection cannot be grounded in defensible assumptions.

What regulatory and clinical datapoints can be used for a defensible timeline?

No cited sources were provided for CEND-1 clinical development (e.g., IND/CTA filings, phase assignment, trial registration, protocol amendments, or safety/efficacy milestones). As a result, there is no allowable basis to compute a development timeline, probability-adjusted launch date, or milestone-driven funding needs.

What is the addressable market and launch revenue outlook for CEND-1?

A market projection requires at least one of the following: indication-specific incidence/prevalence or treated-population estimates, pricing assumptions anchored to comparable therapies, uptake curves tied to label expectations, and competitive intensity by mechanism and line of therapy. None of these inputs are available in the provided information for CEND-1, and there is no cited indication, target product profile, or comparator set to anchor assumptions. Under the constraints, no market forecast can be produced without unsupported assumptions.

What competitive and pricing benchmarks should be applied?

A pricing and competition model requires the indication and label scope (population size, sequencing, endpoints that support payer coverage, and expected differentiation). For CEND-1, those inputs are not present in the provided materials, and no sources are cited for comparators, class pricing, or payer dynamics.

---

Key Takeaways

• A development update for CEND-1 cannot be generated from the provided materials without relying on unverified assumptions about indication, stage, and trial status.
• A market projection cannot be produced without a citable indication, clinical endpoints, and comparator/pricing anchors.

---

FAQs

1. What phase is CEND-1 in?
   Not specified in the provided materials.

2. What indication does CEND-1 target?
   Not specified in the provided materials.

3. Are there public trial results or readouts for CEND-1?
   Not provided in the materials.

4. What is the expected launch timeframe for CEND-1?
   Not determinable from the provided materials.

5. How would CEND-1 be priced and reimbursed?
   Not determinable because no indication, label scope, or comparator pricing data are provided.

---

References (APA)

[No cited sources provided in the prompt.]